Traders should monitor volume of test utilization and future payer additions—especially progress toward the 150M covered lives goal—as key indicators of revenue inflection. Near-term upside possible on continued commercial momentum.
Price Chart
Executive Summary
Plus Therapeutics announced a payer coverage agreement with Highmark, effective April 1, 2026, for its CNSide® CSF tumor test, expanding covered lives from 67 million to 75 million. This strengthens commercial traction and reduces reimbursement barriers, supporting broader adoption across U.S. oncology centers.
Key Facts
- CNSide Diagnostics (a subsidiary of Plus Therapeutics) secured a payer agreement with Highmark for reimbursement of its CNSide® CSF Tumor Cell Enumeration (TCE) assay.
- Effective April 1, 2026, the agreement expands total covered lives from 67 million to 75 million.
- Highmark is a Blue Cross Blue Shield-affiliated payer with nearly 8 million members nationwide.
- CNSide is now covered by major payers including UnitedHealthcare, Humana, and Highmark.
- Over 11,000 CNSide tests have been performed at 120+ U.S. cancer institutions since 2020.
Financial Impact
Expansion to 75M covered lives increases revenue potential; ~40% reduction in healthcare costs supports payer value proposition
Risk Factors
- Revenue realization depends on actual test adoption by physicians, not just payer coverage.
- Company remains pre-profitability; future dilution risk if additional capital is needed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3267245 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 21, 2026 14w ago | Press Release | $3.92 | awaiting T+20 | — | — |
Jun 30, 2026 17w ago | Press Release | $4.37 $3.73 | ▼ −14.65% | ▼ −13.62% | — |
Jun 8, 2026 20w ago | EFFECT | $5.53 $4.05 | ▲ +26.76% | ▲ +28.39% | — |
Jun 5, 2026 20w ago | S-3/A | $5.41 $4.05 | ▼ −25.14% | ▼ −27.00% | — |
May 19, 2026 23w ago | Press Release | $5.83 $4.31 | ▼ −26.07% | ▼ −27.06% | — |
May 15, 2026 23w ago | Press Release | $5.84 $4.57 | ▲ +21.75% | ▲ +23.33% | — |
May 8, 2026 24w ago | Press Release | $6.12 $5.41 | ▼ −11.60% | ▼ −11.62% | — |
Apr 28, 2026 26w ago | Press Release | $5.95 $6.60 | ▲ +10.92% | ▲ +5.46% | — |
Apr 21, 2026 27w ago | 8-K | $7.14 $5.84 | ▼ −18.21% | ▼ −23.12% | — |
Apr 9, 2026 28w ago | 8-K | $3.92 $6.00 | ▲ +53.06% | ▲ +45.49% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers